Truist Financial Keeps Their Buy Rating on Tenet Healthcare (THC)

In a report released yesterday, David S Macdonald from Truist Financial maintained a Buy rating on Tenet Healthcare, with a price target of $270.00.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, S Macdonald is a 5-star analyst with an average return of 10.6% and a 58.20% success rate. S Macdonald covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Tenet Healthcare, and PACS Group Inc.

In addition to Truist Financial, Tenet Healthcare also received a Buy from Barclays’s Andrew Mok CFA in a report issued on February 13. However, on the same day, TipRanks – OpenAI reiterated a Hold rating on Tenet Healthcare (NYSE: THC).

Based on Tenet Healthcare’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.53 billion and a net profit of $371 million. In comparison, last year the company earned a revenue of $5.07 billion and had a net profit of $318 million

Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of THC in relation to earlier this year. Most recently, in December 2025, Nadja West, a Director at THC sold 2,178.00 shares for a total of $430,089.66.